Cube Labs S.p.A. ("Cube Labs" or "the Company") - an Italian venture builder in the healthcare technology sector and listed on the Euronext Growth Milan market, Professional segment - announces that today the Board of Directors of the Company has decided to proceed with a placement ("Placement") of up to 250,000 ("New Shares"), with no nominal value, with regular entitlements, having the same rights as the shares currently in circulation, for a maximum value of Euro 500,000.00, including a premium. The New Shares are derived from the capital increase approved by the shareholders' meeting on January 23, 2023, in support of the listing operation, with a final subscription deadline set for December 31, 2023, for an amount of up to Euro 8,000,000.00, including a premium, with the issuance of a total of 2,052,500 ordinary shares at an issue price of Euro 2.00 per share (of which Euro 0.03 to be allocated to share capital and Euro 1.97 as a premium).
The Placement is aimed at qualified Italian and/or foreign investors (except for Australia, Canada, Japan, and the United States of America). The Placement, in the event of full subscription of the New Shares, will increase the number of shares to 17,852,500 and the free float of the Company up to 15.98%, expanding and diversifying, at the same time, its shareholder base.
The subscription price for the New Shares is Euro 2.00 per share (of which Euro 0.03 to be allocated to share capital and Euro 1.97 as a premium). The Placement begins today and will close on December 22, 2023. The final terms of the offer will be promptly communicated to the market.
(NEWS Traderlink)